<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02933320</url>
  </required_header>
  <id_info>
    <org_study_id>CRUKD16001</org_study_id>
    <secondary_id>2015-004999-29</secondary_id>
    <nct_id>NCT02933320</nct_id>
  </id_info>
  <brief_title>BI-1206 and an Anti-CD20 Antibody in Patients With CD32b Positive B-cell Lymphoma or Leukaemia</brief_title>
  <official_title>A Cancer Research UK Phase I/IIa Clinical Trial of BI-1206; an Antibody to FcƔRIIB (CD32b), as a Single Agent and in Combination With an Anti-CD20 Antibody in Patients With CD32b Positive B-cell Malignancy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Cancer Research UK</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>BioInvent International AB</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Bloodwise</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Cancer Research UK</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this trial is to identify the tolerable dose of BI-1206 (both alone and in&#xD;
      combination) for patients with B-cell lymphoma and leukaemia and further evaluate BI-1206&#xD;
      alone and in combination with an anti-CD20 antibody.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The molecule CD32b is thought to be present on many B-cells including the malignant B-cells&#xD;
      in some types of lymphoma and leukaemia. The study drug, BI-1206, is an anti-CD32b monoclonal&#xD;
      antibody which attaches to CD32b on the surface of B-cells and is thought to act by&#xD;
      recruiting host immune cells toward the tumour leading to cancer cell death as well as&#xD;
      enhancing the anti-cancer effect of other anti-CD20 antibodies such as rituximab by stopping&#xD;
      them being absorbed by cells.&#xD;
&#xD;
      The study is a first in man clinical trial of the drug called BI-1206 on its own and then&#xD;
      also in combination with an anti-CD20 antibody (such as rituximab) which is commonly used to&#xD;
      treat lymphoma and some types of leukaemia.&#xD;
&#xD;
      The four main aims of this trial are to find out:&#xD;
&#xD;
        -  The maximum dose of BI-1206 that can be given safely to patients (to a maximum dose of&#xD;
           800mg) on it's own and in combination with an anti-CD20 antibody, rituximab.&#xD;
&#xD;
        -  More about the potential side effects of BI-1206 and how they can be managed.&#xD;
&#xD;
        -  What happens to BI-1206 inside the body.&#xD;
&#xD;
        -  The effect of BI-1206 treatment (with or without rituximab) on tumour size and survival.&#xD;
&#xD;
      Approximately 81 patients with relapsed or refractory CD32b positive B-cell lymphoma or&#xD;
      leukaemia were planned for the trial. Approximately 34 patients to establish the maximum&#xD;
      tolerated doses (MTDs) in Part A and a further 40 to 50 patients recruited to two expansion&#xD;
      cohorts; one of BI-1206 alone and one of BI-1206 plus rituximab (Part B). The final number&#xD;
      depending on the number of dose escalations required to reach the MTD.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">October 27, 2016</start_date>
  <completion_date type="Actual">March 19, 2020</completion_date>
  <primary_completion_date type="Actual">March 19, 2020</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Documenting Adverse Events (AEs), Serious Adverse Events (SAEs), Dose Limiting Toxicities (DLTs) (Graded According to NCI-CTCAE Version 4.02) and Laboratory Parameters and Determining Their Causality in Relation to BI-1206.</measure>
    <time_frame>Safety data were collected from the date of written informed consent and continued for 125 days after the final administration of BI-1206 or rituximab.</time_frame>
    <description>To recommend a dose for future trials with BI-1206 by finding the highest safe dose which can be given to patients.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Documenting AEs, SAEs (Graded According to NCI-CTCAE Version 4.02) and Laboratory Parameters and Determining Their Causality in Relation to BI-1206 and, Where Appropriate, Anti-CD20 Antibody.</measure>
    <time_frame>Safety data were collected from the date of written informed consent and continued for 125 days after the final administration of BI-1206 or rituximab.</time_frame>
    <description>Establishing the MTD or maximum administered dose MAD of BI-1206 and an anti-CD20 antibody given once weekly for four weeks, via intravenous infusion in patients with relapsed or refractory B-cell malignancies.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Measurement of PK Parameter Maximum Observed Serum Concentration (Cmax) for BI-1206</measure>
    <time_frame>Doses 1 and 4 (pre-infusion, end of infusion, +4, +24, +48 and +72 hours)</time_frame>
    <description>Maximum observed serum concentration after intravenous BI-1206 administration</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Measurement of PK Parameter Area Under the Serum Concentration-time Curve From Time 0 to the Last Time Point (AUClast) for BI-1206</measure>
    <time_frame>Doses 1 and 4 (pre-infusion, end of infusion, +4, +24, +48 and +72 hours)</time_frame>
    <description>Area under the serum concentration-time curve from time 0 to the last time point after intravenous BI-1206 administration.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Measurement of PK Parameter Half-life (T1/2) for BI-1206</measure>
    <time_frame>Doses 1 and 4 (pre-infusion, end of infusion, +4, +24, +48 and +72 hours)</time_frame>
    <description>BI-1206 half-life after intravenous administration</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Measurement of PK Parameter Total Body Clearance (CL) for BI-1206</measure>
    <time_frame>Doses 1 and 4 (pre-infusion, end of infusion, +4, +24, +48 and +72 hours)</time_frame>
    <description>Total body clearance after intravenous BI-1206 administration</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Measurement of PK Parameter Volume of Distribution (Vss) for BI-1206</measure>
    <time_frame>Doses 1 and 4 (pre-infusion, end of infusion, +4, +24, +48 and +72 hours)</time_frame>
    <description>Volume of distribution after administration of BI-1206</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Measurement of Anti-drug Antibody (ADA) Response to BI-1206 During the BI-1206 Treatment Period Using ELISA</measure>
    <time_frame>Pre dose at weeks 1, 5 and 8, maintenance phase and off-study visit.</time_frame>
    <description>Patients with true ADA response</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Measurement of Peripheral Blood B-lymphocyte Depletion During the BI-1206 Treatment Period Using Flow Cytometry.</measure>
    <time_frame>During induction phase (up to 8 weeks).</time_frame>
    <description>Number of patients with B-lymphocyte depletion during BI-1206 treatment period.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assessment of Best Disease Response According to Criteria for Malignant Lymphoma (Cheson, 2014) Waldenström Macroglobulinaemia Assessment Criteria (Owen 2013, Kimby 2006) or NCI Chronic Lymphocytic Leukaemia (CLL) Criteria (Hallek, 2008).</measure>
    <time_frame>Response evaluated 4 weeks after last dose in induction phase, every 16 weeks during maintenance phase and at off-study.</time_frame>
    <description>To look for signs of anti-tumour activity of BI-1206 alone and in combination in patients with relapsed or refractory B-cell malignancies</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Measure Progression Free Survival at 1 Year After the First BI-1206 Administration on the Study for All Patients</measure>
    <time_frame>From first BI-1206 administration up to 12 months</time_frame>
    <description>To measure the time to disease progression and twelve month survival</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Measure Overall Survival at 1 Year After the First BI-1206 Administration on the Study for All Patients</measure>
    <time_frame>From first BI-1206 administration up to 12 months. Participants whose last reported status was not death were censored.</time_frame>
    <description>To measure the time to disease progression and twelve month survival</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">14</enrollment>
  <condition>B-cell Lymphoma</condition>
  <condition>Chronic Lymphocytic Leukaemia</condition>
  <condition>Waldenström Macroglobulinemia</condition>
  <arm_group>
    <arm_group_label>Part A: Arm 1: BI-1206 single agent dose escalation phase</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>BI-1206 given by IV infusion to all patients once weekly for a period of four weeks, patients will then have a follow-up period of four weeks (8 week period classified as induction therapy).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part A: Arm 2: Combination of BI-1206 with rituximab escalation phase</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Arm 2, an investigation of combination treatment of BI-1206 with rituximab, involving an initial assessment of the appropriate dose of BI-1206 that can be given in combination with rituximab (combination dose escalation cohorts).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part B: Arm1: BI-1206 single agent expansion phase</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Part B Arm 1, an expansion cohort of up to 25 patients treated with single agent BI-1206 at the RP2D as determined in Part A Arm 1. Expansion to include a minimum of 12 chronic lymphocytic leukaemia (CLL) patients and six mantle cell lymphoma (MCL) patients.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part B: Arm 2: Combination of BI-1206 with rituximab expansion phase</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Part B Arm 2, an expansion cohort of up to 25 patients treated with a combination of BI-1206 and rituximab at the RP2D as determined in Part A Arm 2. Expansion to include a minimum of 12 CLL patients and six MCL patients.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>BI-1206 single agent dose escalation phase</intervention_name>
    <description>BI-1206 single agent dose escalation phase to determine the MTD or maximum administered dose (MAD) and recommended Phase II dose (RP2D) for evaluation of BI-1206.</description>
    <arm_group_label>Part A: Arm 1: BI-1206 single agent dose escalation phase</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Combination of BI-1206 with rituximab escalation phase</intervention_name>
    <description>An investigation of combination treatment of BI-1206 with rituximab.</description>
    <arm_group_label>Part A: Arm 2: Combination of BI-1206 with rituximab escalation phase</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>BI-1206 single agent expansion phase</intervention_name>
    <description>BI-1206 single agent expansion phase at the RP2D.</description>
    <arm_group_label>Part B: Arm1: BI-1206 single agent expansion phase</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Combination of BI-1206 with rituximab expansion phase</intervention_name>
    <description>BI-1206 in combination with rituximab at the RP2D.</description>
    <arm_group_label>Part B: Arm 2: Combination of BI-1206 with rituximab expansion phase</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Written (signed and dated) informed consent and be capable of co-operating with&#xD;
             treatment and follow-up.&#xD;
&#xD;
          2. B-cell lymphoma or CLL proven by histology or flow cytometry, relapsed or refractory&#xD;
             to conventional treatment, or for which no conventional therapy exists or is declined&#xD;
             by the patient. Patients should have received at least one line of conventional&#xD;
             previous therapy which must have included a rituximab based regimen.&#xD;
&#xD;
          3. CD32b positive malignancy as demonstrated centrally by immunohistochemistry or flow&#xD;
             cytometry prior to study entry. Available tissue or blood must have been taken within&#xD;
             six months of study entry.&#xD;
&#xD;
          4. Life expectancy of at least 12 weeks.&#xD;
&#xD;
          5. World Health Organisation (WHO) performance status of 0-2 (Appendix 1).&#xD;
&#xD;
          6. Haematological and biochemical indices within the ranges shown below. These&#xD;
             measurements must be performed within one week before their first dose of mAb (BI-1206&#xD;
             and/or rituximab) as part of this study.&#xD;
&#xD;
             Laboratory Test Value required&#xD;
&#xD;
             Haemoglobin (Hb) ≥9.0 g/dL (red cell support is permissible)&#xD;
&#xD;
             Absolute neutrophil count (ANC) ≥1.0 x 10^9/L (or &gt;0.5 x 10^9/L if due to lymphoma),&#xD;
             granulocyte - colony stimulating factor (G-CSF) support is not permissible at&#xD;
             screening&#xD;
&#xD;
             Platelet count ≥50 x 10^9/L (or ≥30 x 10^9/L if due to malignant involvement of bone&#xD;
             marrow)&#xD;
&#xD;
             Either:&#xD;
&#xD;
             Serum bilirubin ≤1.5 x upper limit of normal (ULN) unless raised due to Gilbert's&#xD;
             syndrome in which case up to 3 x ULN is permissible.&#xD;
&#xD;
             Or:&#xD;
&#xD;
             Alanine amino-transferase (ALT) and /or aspartate amino-transferase (AST) ≤ 2.5 x ULN&#xD;
             unless raised due to malignant hepatic involvement in which case up to 5 x ULN is&#xD;
             permissible&#xD;
&#xD;
             Either:&#xD;
&#xD;
             Calculated creatinine clearance (Cockcroft Gault) ≥30 mL/min (uncorrected value)&#xD;
&#xD;
             Or:&#xD;
&#xD;
             Isotope clearance measurement ≥30 mL/min (corrected)&#xD;
&#xD;
          7. 18 years or over.&#xD;
&#xD;
          8. B-cell lymphoma patients only: patients has at least one measurable lesion by CT scan&#xD;
             (defined as greater than 1.5 cm in one axis) or in the case of Waldenström's&#xD;
             macroglobulinemia, disease must be assessable by the criteria stated in Appendix 6 of&#xD;
             the protocol.&#xD;
&#xD;
          9. Patients recruited to Arm 2 in Parts A and B (combination arms) only: CD20 positive&#xD;
             malignancy as demonstrated by immunohistochemistry or flow cytometry prior to trial&#xD;
             entry.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Allogenic bone marrow transplant within 12 months prior to the first dose of BI-1206&#xD;
             or presence of chronic graft versus host disease.&#xD;
&#xD;
          2. Patients with clinically active leptomeningeal or central nervous system&#xD;
             lymphoma/leukaemia.&#xD;
&#xD;
          3. Doses of prednisolone &gt;10 mg daily (or equipotent doses of other corticosteroids) are&#xD;
             not permitted whilst on the study other than as pre-medication. During the screening&#xD;
             period, doses of up to 20 mg per day may be given but the dose must be reduced to 10&#xD;
             mg/day by Cycle 1 Day 1 (or Day -7 in the CLL combination expansion).&#xD;
&#xD;
          4. Known or suspected hypersensitivity to study drugs.&#xD;
&#xD;
          5. Cardiac or renal amyloid light-chain (AL) amyloidosis.&#xD;
&#xD;
          6. Radiotherapy, endocrine therapy, immunotherapy, chemotherapy or investigational&#xD;
             medicinal products during the previous 4 weeks before treatment.&#xD;
&#xD;
          7. Ongoing toxic manifestations of previous treatments. Exceptions to this are alopecia&#xD;
             or certain Grade 1 toxicities, which in the opinion of the Investigator and the&#xD;
             Sponsor should not exclude the patient.&#xD;
&#xD;
          8. Ability to become pregnant (or already pregnant or lactating). However, those female&#xD;
             patients who have a negative serum or urine pregnancy test before enrolment and agree&#xD;
             to use two forms of contraception (one highly effective form plus a barrier method)&#xD;
             [oral, injected or implanted hormonal contraception and condom; intra-uterine device&#xD;
             and condom; diaphragm with spermicidal gel and condom] or agree to sexual abstinence^4&#xD;
             for four weeks before entering the trial, during the trial and for twelve months after&#xD;
             completing treatment are considered eligible.&#xD;
&#xD;
          9. Male patients with partners of child-bearing potential (unless they agree to take&#xD;
             measures not to father children by using a barrier method of contraception [condom&#xD;
             plus spermicide] or to sexual abstinence effective from the first administration of&#xD;
             BI-1206 or rituximab on the study, throughout the trial and for twelve months&#xD;
             afterwards. Men with partners of child-bearing potential must also be willing to&#xD;
             ensure that their partner uses an effective method of contraception for the same&#xD;
             duration for example, hormonal contraception, intrauterine device, diaphragm with&#xD;
             spermicidal gel or sexual abstinence4). Men with pregnant or lactating partners should&#xD;
             be advised to use barrier method contraception (e.g. condom plus spermicidal gel) to&#xD;
             prevent exposure to the foetus or neonate.&#xD;
&#xD;
         10. Major thoracic or abdominal surgery from which the patient has not yet recovered.&#xD;
&#xD;
         11. At high medical risk because of non-malignant systemic disease including infection.&#xD;
&#xD;
         12. Known to be serologically positive for Hepatitis B, Hepatitis C or Human&#xD;
             Immunodeficiency Virus (HIV).&#xD;
&#xD;
         13. Patients with an active, known or suspected autoimmune disease (not including CLL&#xD;
             auto-immune disease). Patients with Type I diabetes mellitus, hypothyroidism only&#xD;
             requiring hormone replacement, skin disorders (such as vitiligo, psoriasis, or&#xD;
             alopecia) not requiring systemic treatment, or conditions not expected to recur in the&#xD;
             absence of an external trigger will be permitted to participate.&#xD;
&#xD;
         14. Concurrent congestive heart failure, prior history of class III/ IV cardiac disease&#xD;
             (New York Heart Association [NYHA]), prior history of cardiac ischaemia or prior&#xD;
             history of cardiac arrhythmia.&#xD;
&#xD;
         15. Patients for whom rituximab is contraindicated due to severe previous hypersensitivity&#xD;
             or any other reason (Arm 2 in Parts A and B [combination arms] only).&#xD;
&#xD;
         16. Ongoing infection requiring treatment with antibiotics, antifungals or antivirals.&#xD;
             Prophylactic use of antibiotics, antifungals or antivirals would not have excluded&#xD;
             patients.&#xD;
&#xD;
         17. Any other condition which in the Investigator's opinion would not make the patient a&#xD;
             good candidate for the clinical trial.&#xD;
&#xD;
         18. Is a participant or plans to participate in another interventional clinical study,&#xD;
             whilst taking part in this Phase I/IIa study of BI-1206. Participation in an&#xD;
             observational study would be acceptable.&#xD;
&#xD;
         19. Current malignancies of other types, with the exception of adequately treated&#xD;
             cone-biopsied in situ carcinoma of the cervix uteri and basal or squamous cell&#xD;
             carcinoma of the skin. Cancer survivors, who have undergone potentially curative&#xD;
             therapy for a prior malignancy, have no evidence of that disease for three years or&#xD;
             more and are deemed at negligible risk for recurrence, are eligible for the trial.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Andrew Davies, Prof</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Southampton</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Leicester Royal Infirmary</name>
      <address>
        <city>Leicester</city>
        <state>England</state>
        <zip>LE1 5WW</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Christie Hospital</name>
      <address>
        <city>Manchester</city>
        <state>England</state>
        <zip>M20 4BX</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Oxford Cancer and Haematology Centre, Churchill Hospital</name>
      <address>
        <city>Oxford</city>
        <state>England</state>
        <zip>OX3 7LE</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Derriford Hospital</name>
      <address>
        <city>Plymouth</city>
        <zip>PL6 8DH</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Hospital Southampton NHS Foundation Trust</name>
      <address>
        <city>Southampton</city>
        <zip>S016 6YD</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>June 2021</verification_date>
  <study_first_submitted>September 26, 2016</study_first_submitted>
  <study_first_submitted_qc>October 13, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 14, 2016</study_first_posted>
  <results_first_submitted>March 21, 2021</results_first_submitted>
  <results_first_submitted_qc>June 17, 2021</results_first_submitted_qc>
  <results_first_posted type="Actual">July 8, 2021</results_first_posted>
  <last_update_submitted>June 17, 2021</last_update_submitted>
  <last_update_submitted_qc>June 17, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">July 8, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Indolent B-cell Lymphoma</keyword>
  <keyword>Chronic Lymphocytic Leukaemia</keyword>
  <keyword>Waldenström Macroglobulinemia</keyword>
  <keyword>BI-1206</keyword>
  <keyword>CD32b</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Leukemia, Lymphoid</mesh_term>
    <mesh_term>Leukemia, Lymphocytic, Chronic, B-Cell</mesh_term>
    <mesh_term>Lymphoma, B-Cell</mesh_term>
    <mesh_term>Waldenstrom Macroglobulinemia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Rituximab</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>September 3, 2019</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/20/NCT02933320/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Trial participants were enrolled at four trial sites between 27 October 2016 and 09 December 2019.</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>Part A: Arm 1: BI-1206 Single Agent Dose Escalation Phase</title>
          <description>BI-1206 given by IV infusion to all patients once weekly for a period of four weeks, patients will then have a follow-up period of four weeks (8 week period classified as induction therapy).&#xD;
BI-1206 single agent dose escalation phase: BI-1206 single agent dose escalation phase to determine the MTD or MAD and RP2D for evaluation of BI-1206.</description>
        </group>
        <group group_id="P2">
          <title>Part A: Arm 2: Combination of BI-1206 With Rituximab Escalation Phase</title>
          <description>Arm 2, an investigation of combination treatment of BI-1206 with rituximab, involving an initial assessment of the appropriate dose of BI-1206 that can be given in combination with rituximab (combination dose escalation cohorts).&#xD;
Combination of BI-1206 with rituximab escalation phase: An investigation of combination treatment of BI-1206 with rituximab.</description>
        </group>
        <group group_id="P3">
          <title>Part B: Arm1: BI-1206 Single Agent Expansion Phase</title>
          <description>Part B Arm 1, an expansion cohort of up to 25 patients treated with single agent BI-1206 at the RP2D as determined in Part A Arm 1. Expansion to include a minimum of 12 CLL patients and six MCL patients.&#xD;
BI-1206 single agent expansion phase: BI-1206 single agent expansion phase at the RP2D.</description>
        </group>
        <group group_id="P4">
          <title>Part B: Arm 2: Combination of BI-1206 With Rituximab Expansion Phase</title>
          <description>Part B Arm 2, an expansion cohort of up to 25 patients treated with a combination of BI-1206 and rituximab at the RP2D as determined in Part A Arm 2. Expansion to include a minimum of 12 CLL patients and six MCL patients.&#xD;
Combination of BI-1206 with rituximab expansion phase: BI-1206 in combination with rituximab at the RP2D.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="13"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0">Trial terminated early</participants>
                <participants group_id="P4" count="0">Trial terminated early</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="13"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Trial terminated before opening Part B.</population>
      <group_list>
        <group group_id="B1">
          <title>Part A: Arm 1: BI-1206 Single Agent Dose Escalation Phase</title>
          <description>BI-1206 given by IV infusion to all patients once weekly for a period of four weeks, patients will then have a follow-up period of four weeks (8 week period classified as induction therapy).&#xD;
BI-1206 single agent dose escalation phase: BI-1206 single agent dose escalation phase to determine the MTD or MAD and RP2D for evaluation of BI-1206.</description>
        </group>
        <group group_id="B2">
          <title>Part A: Arm 2: Combination of BI-1206 With Rituximab Escalation Phase</title>
          <description>Arm 2, an investigation of combination treatment of BI-1206 with rituximab, involving an initial assessment of the appropriate dose of BI-1206 that can be given in combination with rituximab (combination dose escalation cohorts).&#xD;
Combination of BI-1206 with rituximab escalation phase: An investigation of combination treatment of BI-1206 with rituximab.</description>
        </group>
        <group group_id="B3">
          <title>Part B: Arm1: BI-1206 Single Agent Expansion Phase</title>
          <description>Part B Arm 1, an expansion cohort of up to 25 patients treated with single agent BI-1206 at the RP2D as determined in Part A Arm 1. Expansion to include a minimum of 12 CLL patients and six MCL patients.&#xD;
BI-1206 single agent expansion phase: BI-1206 single agent expansion phase at the RP2D.</description>
        </group>
        <group group_id="B4">
          <title>Part B: Arm 2: Combination of BI-1206 With Rituximab Expansion Phase</title>
          <description>Part B Arm 2, an expansion cohort of up to 25 patients treated with a combination of BI-1206 and rituximab at the RP2D as determined in Part A Arm 2. Expansion to include a minimum of 12 CLL patients and six MCL patients.&#xD;
Combination of BI-1206 with rituximab expansion phase: BI-1206 in combination with rituximab at the RP2D.</description>
        </group>
        <group group_id="B5">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="13"/>
            <count group_id="B2" value="1"/>
            <count group_id="B3" value="0"/>
            <count group_id="B4" value="0"/>
            <count group_id="B5" value="14"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="13"/>
                    <count group_id="B2" value="1"/>
                    <count group_id="B3" value="0"/>
                    <count group_id="B4" value="0"/>
                    <count group_id="B5" value="14"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B5" value="6"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B5" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="13"/>
                    <count group_id="B2" value="1"/>
                    <count group_id="B3" value="0"/>
                    <count group_id="B4" value="0"/>
                    <count group_id="B5" value="14"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B5" value="6"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B5" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race and Ethnicity Not Collected</title>
          <population>Race and Ethnicity were not collected from any participant.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="0"/>
                    <count group_id="B2" value="0"/>
                    <count group_id="B3" value="0"/>
                    <count group_id="B4" value="0"/>
                    <count group_id="B5" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United Kingdom</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="13"/>
                    <count group_id="B2" value="1"/>
                    <count group_id="B3" value="0"/>
                    <count group_id="B4" value="0"/>
                    <count group_id="B5" value="14"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="13"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B5" value="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Documenting Adverse Events (AEs), Serious Adverse Events (SAEs), Dose Limiting Toxicities (DLTs) (Graded According to NCI-CTCAE Version 4.02) and Laboratory Parameters and Determining Their Causality in Relation to BI-1206.</title>
        <description>To recommend a dose for future trials with BI-1206 by finding the highest safe dose which can be given to patients.</description>
        <time_frame>Safety data were collected from the date of written informed consent and continued for 125 days after the final administration of BI-1206 or rituximab.</time_frame>
        <population>Safety population</population>
        <group_list>
          <group group_id="O1">
            <title>Part A: Arm 1: BI-1206 Single Agent Dose Escalation Phase</title>
            <description>BI-1206 given by IV infusion to all patients once weekly for a period of four weeks, patients will then have a follow-up period of four weeks (8 week period classified as induction therapy).&#xD;
BI-1206 single agent dose escalation phase: BI-1206 single agent dose escalation phase to determine the MTD or MAD and RP2D for evaluation of BI-1206.</description>
          </group>
          <group group_id="O2">
            <title>Part A: Arm 2: Combination of BI-1206 With Rituximab Escalation Phase</title>
            <description>Arm 2, an investigation of combination treatment of BI-1206 with rituximab, involving an initial assessment of the appropriate dose of BI-1206 that can be given in combination with rituximab (combination dose escalation cohorts).&#xD;
Combination of BI-1206 with rituximab escalation phase: An investigation of combination treatment of BI-1206 with rituximab.</description>
          </group>
          <group group_id="O3">
            <title>Part B: Arm1: BI-1206 Single Agent Expansion Phase</title>
            <description>Part B Arm 1, an expansion cohort of up to 25 patients treated with single agent BI-1206 at the RP2D as determined in Part A Arm 1. Expansion to include a minimum of 12 CLL patients and six MCL patients.&#xD;
BI-1206 single agent expansion phase: BI-1206 single agent expansion phase at the RP2D.</description>
          </group>
          <group group_id="O4">
            <title>Part B: Arm 2: Combination of BI-1206 With Rituximab Expansion Phase</title>
            <description>Part B Arm 2, an expansion cohort of up to 25 patients treated with a combination of BI-1206 and rituximab at the RP2D as determined in Part A Arm 2. Expansion to include a minimum of 12 CLL patients and six MCL patients.&#xD;
Combination of BI-1206 with rituximab expansion phase: BI-1206 in combination with rituximab at the RP2D.</description>
          </group>
        </group_list>
        <measure>
          <title>Documenting Adverse Events (AEs), Serious Adverse Events (SAEs), Dose Limiting Toxicities (DLTs) (Graded According to NCI-CTCAE Version 4.02) and Laboratory Parameters and Determining Their Causality in Relation to BI-1206.</title>
          <description>To recommend a dose for future trials with BI-1206 by finding the highest safe dose which can be given to patients.</description>
          <population>Safety population</population>
          <units>Number of events</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="13"/>
                <count group_id="O2" value="1"/>
                <count group_id="O3" value="0"/>
                <count group_id="O4" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>All AEs</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="282"/>
                    <measurement group_id="O2" value="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Related AEs</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="214"/>
                    <measurement group_id="O2" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DLT - ALT</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DLT - AST</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DLT - infusion related reaction</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Documenting AEs, SAEs (Graded According to NCI-CTCAE Version 4.02) and Laboratory Parameters and Determining Their Causality in Relation to BI-1206 and, Where Appropriate, Anti-CD20 Antibody.</title>
        <description>Establishing the MTD or maximum administered dose MAD of BI-1206 and an anti-CD20 antibody given once weekly for four weeks, via intravenous infusion in patients with relapsed or refractory B-cell malignancies.</description>
        <time_frame>Safety data were collected from the date of written informed consent and continued for 125 days after the final administration of BI-1206 or rituximab.</time_frame>
        <population>Safety population</population>
        <group_list>
          <group group_id="O1">
            <title>Part A: Arm 1: BI-1206 Single Agent Dose Escalation Phase</title>
            <description>BI-1206 given by IV infusion to all patients once weekly for a period of four weeks, patients will then have a follow-up period of four weeks (8 week period classified as induction therapy).&#xD;
BI-1206 single agent dose escalation phase: BI-1206 single agent dose escalation phase to determine the MTD or MAD and RP2D for evaluation of BI-1206.</description>
          </group>
          <group group_id="O2">
            <title>Part A: Arm 2: Combination of BI-1206 With Rituximab Escalation Phase</title>
            <description>Arm 2, an investigation of combination treatment of BI-1206 with rituximab, involving an initial assessment of the appropriate dose of BI-1206 that can be given in combination with rituximab (combination dose escalation cohorts).&#xD;
Combination of BI-1206 with rituximab escalation phase: An investigation of combination treatment of BI-1206 with rituximab.</description>
          </group>
          <group group_id="O3">
            <title>Part B: Arm1: BI-1206 Single Agent Expansion Phase</title>
            <description>Part B Arm 1, an expansion cohort of up to 25 patients treated with single agent BI-1206 at the RP2D as determined in Part A Arm 1. Expansion to include a minimum of 12 CLL patients and six MCL patients.&#xD;
BI-1206 single agent expansion phase: BI-1206 single agent expansion phase at the RP2D.</description>
          </group>
          <group group_id="O4">
            <title>Part B: Arm 2: Combination of BI-1206 With Rituximab Expansion Phase</title>
            <description>Part B Arm 2, an expansion cohort of up to 25 patients treated with a combination of BI-1206 and rituximab at the RP2D as determined in Part A Arm 2. Expansion to include a minimum of 12 CLL patients and six MCL patients.&#xD;
Combination of BI-1206 with rituximab expansion phase: BI-1206 in combination with rituximab at the RP2D.</description>
          </group>
        </group_list>
        <measure>
          <title>Documenting AEs, SAEs (Graded According to NCI-CTCAE Version 4.02) and Laboratory Parameters and Determining Their Causality in Relation to BI-1206 and, Where Appropriate, Anti-CD20 Antibody.</title>
          <description>Establishing the MTD or maximum administered dose MAD of BI-1206 and an anti-CD20 antibody given once weekly for four weeks, via intravenous infusion in patients with relapsed or refractory B-cell malignancies.</description>
          <population>Safety population</population>
          <units>BI-1206 MAD (mg)</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="13"/>
                <count group_id="O2" value="1"/>
                <count group_id="O3" value="0"/>
                <count group_id="O4" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100"/>
                    <measurement group_id="O2" value="NA">50 mg BI-1206 given but not rituximab</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Measurement of PK Parameter Maximum Observed Serum Concentration (Cmax) for BI-1206</title>
        <description>Maximum observed serum concentration after intravenous BI-1206 administration</description>
        <time_frame>Doses 1 and 4 (pre-infusion, end of infusion, +4, +24, +48 and +72 hours)</time_frame>
        <population>Patients who provided serum samples before and after receiving BI-1206 for pharmacokinetic evaluation. One patient was enrolled to Part A, Arm 2 but PK parameters could not be evaluated for this patient, as there were no post-dose samples taken for the patient recruited to this cohort.</population>
        <group_list>
          <group group_id="O1">
            <title>Part A: Arm 1: BI-1206 Single Agent Dose Escalation Phase</title>
            <description>BI-1206 given by IV infusion to all patients once weekly for a period of four weeks, patients will then have a follow-up period of four weeks (8 week period classified as induction therapy).&#xD;
BI-1206 single agent dose escalation phase: BI-1206 single agent dose escalation phase to determine the MTD or MAD and RP2D for evaluation of BI-1206.</description>
          </group>
          <group group_id="O2">
            <title>Part A: Arm 2: Combination of BI-1206 With Rituximab Escalation Phase</title>
            <description>Arm 2, an investigation of combination treatment of BI-1206 with rituximab, involving an initial assessment of the appropriate dose of BI-1206 that can be given in combination with rituximab (combination dose escalation cohorts).&#xD;
Combination of BI-1206 with rituximab escalation phase: An investigation of combination treatment of BI-1206 with rituximab.</description>
          </group>
          <group group_id="O3">
            <title>Part B: Arm1: BI-1206 Single Agent Expansion Phase</title>
            <description>Part B Arm 1, an expansion cohort of up to 25 patients treated with single agent BI-1206 at the RP2D as determined in Part A Arm 1. Expansion to include a minimum of 12 CLL patients and six MCL patients.&#xD;
BI-1206 single agent expansion phase: BI-1206 single agent expansion phase at the RP2D.</description>
          </group>
          <group group_id="O4">
            <title>Part B: Arm 2: Combination of BI-1206 With Rituximab Expansion Phase</title>
            <description>Part B Arm 2, an expansion cohort of up to 25 patients treated with a combination of BI-1206 and rituximab at the RP2D as determined in Part A Arm 2. Expansion to include a minimum of 12 CLL patients and six MCL patients.&#xD;
Combination of BI-1206 with rituximab expansion phase: BI-1206 in combination with rituximab at the RP2D.</description>
          </group>
        </group_list>
        <measure>
          <title>Measurement of PK Parameter Maximum Observed Serum Concentration (Cmax) for BI-1206</title>
          <description>Maximum observed serum concentration after intravenous BI-1206 administration</description>
          <population>Patients who provided serum samples before and after receiving BI-1206 for pharmacokinetic evaluation. One patient was enrolled to Part A, Arm 2 but PK parameters could not be evaluated for this patient, as there were no post-dose samples taken for the patient recruited to this cohort.</population>
          <units>ng/mL</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="0"/>
                <count group_id="O3" value="0"/>
                <count group_id="O4" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>0.4 - 50 mg BI-1206 (Cohort 1, intra patient dose escalation)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6075" lower_limit="31.2" upper_limit="13100"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>100 mg BI-1206 (Cohort 2) Dose 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15600" lower_limit="6990" upper_limit="19300"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>100 mg BI-1206 (Cohort 2) Dose 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12700" lower_limit="8850" upper_limit="22500"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Measurement of PK Parameter Area Under the Serum Concentration-time Curve From Time 0 to the Last Time Point (AUClast) for BI-1206</title>
        <description>Area under the serum concentration-time curve from time 0 to the last time point after intravenous BI-1206 administration.</description>
        <time_frame>Doses 1 and 4 (pre-infusion, end of infusion, +4, +24, +48 and +72 hours)</time_frame>
        <population>Patients who provided serum samples before and after receiving BI-1206 for pharmacokinetic evaluation. One patient was enrolled to Part A, Arm 2 but PK parameters could not be evaluated for this patient, as there were no post-dose samples taken for the patient recruited to this cohort.</population>
        <group_list>
          <group group_id="O1">
            <title>Part A: Arm 1: BI-1206 Single Agent Dose Escalation Phase</title>
            <description>BI-1206 given by IV infusion to all patients once weekly for a period of four weeks, patients will then have a follow-up period of four weeks (8 week period classified as induction therapy).&#xD;
BI-1206 single agent dose escalation phase: BI-1206 single agent dose escalation phase to determine the MTD or MAD and RP2D for evaluation of BI-1206.</description>
          </group>
          <group group_id="O2">
            <title>Part A: Arm 2: Combination of BI-1206 With Rituximab Escalation Phase</title>
            <description>Arm 2, an investigation of combination treatment of BI-1206 with rituximab, involving an initial assessment of the appropriate dose of BI-1206 that can be given in combination with rituximab (combination dose escalation cohorts).&#xD;
Combination of BI-1206 with rituximab escalation phase: An investigation of combination treatment of BI-1206 with rituximab.</description>
          </group>
          <group group_id="O3">
            <title>Part B: Arm1: BI-1206 Single Agent Expansion Phase</title>
            <description>Part B Arm 1, an expansion cohort of up to 25 patients treated with single agent BI-1206 at the RP2D as determined in Part A Arm 1. Expansion to include a minimum of 12 CLL patients and six MCL patients.&#xD;
BI-1206 single agent expansion phase: BI-1206 single agent expansion phase at the RP2D.</description>
          </group>
          <group group_id="O4">
            <title>Part B: Arm 2: Combination of BI-1206 With Rituximab Expansion Phase</title>
            <description>Part B Arm 2, an expansion cohort of up to 25 patients treated with a combination of BI-1206 and rituximab at the RP2D as determined in Part A Arm 2. Expansion to include a minimum of 12 CLL patients and six MCL patients.&#xD;
Combination of BI-1206 with rituximab expansion phase: BI-1206 in combination with rituximab at the RP2D.</description>
          </group>
        </group_list>
        <measure>
          <title>Measurement of PK Parameter Area Under the Serum Concentration-time Curve From Time 0 to the Last Time Point (AUClast) for BI-1206</title>
          <description>Area under the serum concentration-time curve from time 0 to the last time point after intravenous BI-1206 administration.</description>
          <population>Patients who provided serum samples before and after receiving BI-1206 for pharmacokinetic evaluation. One patient was enrolled to Part A, Arm 2 but PK parameters could not be evaluated for this patient, as there were no post-dose samples taken for the patient recruited to this cohort.</population>
          <units>h*ng/mL</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="0"/>
                <count group_id="O3" value="0"/>
                <count group_id="O4" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>0.4 - 50 mg BI-1206 (Cohort 1, intra patient dose escalation)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="76100" lower_limit="9.1" upper_limit="384000"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>100 mg BI-1206 (Cohort 2) Dose 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="462000" lower_limit="129000" upper_limit="594000"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>100 mg BI-1206 (Cohort 2) Dose 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="193000" lower_limit="168000" upper_limit="733000"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Measurement of PK Parameter Half-life (T1/2) for BI-1206</title>
        <description>BI-1206 half-life after intravenous administration</description>
        <time_frame>Doses 1 and 4 (pre-infusion, end of infusion, +4, +24, +48 and +72 hours)</time_frame>
        <population>Patients who provided serum samples before and after receiving BI-1206 for pharmacokinetic evaluation. One patient was enrolled to Part A, Arm 2 but PK parameters could not be evaluated for this patient, as there were no post-dose samples taken for the patient recruited to this cohort.</population>
        <group_list>
          <group group_id="O1">
            <title>Part A: Arm 1: BI-1206 Single Agent Dose Escalation Phase</title>
            <description>BI-1206 given by IV infusion to all patients once weekly for a period of four weeks, patients will then have a follow-up period of four weeks (8 week period classified as induction therapy).&#xD;
BI-1206 single agent dose escalation phase: BI-1206 single agent dose escalation phase to determine the MTD or MAD and RP2D for evaluation of BI-1206.</description>
          </group>
          <group group_id="O2">
            <title>Part A: Arm 2: Combination of BI-1206 With Rituximab Escalation Phase</title>
            <description>Arm 2, an investigation of combination treatment of BI-1206 with rituximab, involving an initial assessment of the appropriate dose of BI-1206 that can be given in combination with rituximab (combination dose escalation cohorts).&#xD;
Combination of BI-1206 with rituximab escalation phase: An investigation of combination treatment of BI-1206 with rituximab.</description>
          </group>
          <group group_id="O3">
            <title>Part B: Arm1: BI-1206 Single Agent Expansion Phase</title>
            <description>Part B Arm 1, an expansion cohort of up to 25 patients treated with single agent BI-1206 at the RP2D as determined in Part A Arm 1. Expansion to include a minimum of 12 CLL patients and six MCL patients.&#xD;
BI-1206 single agent expansion phase: BI-1206 single agent expansion phase at the RP2D.</description>
          </group>
          <group group_id="O4">
            <title>Part B: Arm 2: Combination of BI-1206 With Rituximab Expansion Phase</title>
            <description>Part B Arm 2, an expansion cohort of up to 25 patients treated with a combination of BI-1206 and rituximab at the RP2D as determined in Part A Arm 2. Expansion to include a minimum of 12 CLL patients and six MCL patients.&#xD;
Combination of BI-1206 with rituximab expansion phase: BI-1206 in combination with rituximab at the RP2D.</description>
          </group>
        </group_list>
        <measure>
          <title>Measurement of PK Parameter Half-life (T1/2) for BI-1206</title>
          <description>BI-1206 half-life after intravenous administration</description>
          <population>Patients who provided serum samples before and after receiving BI-1206 for pharmacokinetic evaluation. One patient was enrolled to Part A, Arm 2 but PK parameters could not be evaluated for this patient, as there were no post-dose samples taken for the patient recruited to this cohort.</population>
          <units>h</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="0"/>
                <count group_id="O3" value="0"/>
                <count group_id="O4" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>0.4 - 2 mg BI-1206 (Cohort 1, starting dose and first intra patient escalation dose)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA" lower_limit="NA" upper_limit="NA">Half-life could not be assessed at these dose levels as insufficient serum concentration values were above the lower limit of detection.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>10 - 50 mg BI-1206 (Cohort 1, intra patient dose escalation)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="17.3" lower_limit="9.3" upper_limit="18.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>100 mg BI-1206 (Cohort 2) Dose 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16" lower_limit="11.5" upper_limit="21.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>100 mg BI-1206 (Cohort 2) Dose 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12.1" lower_limit="10.8" upper_limit="46.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Measurement of PK Parameter Total Body Clearance (CL) for BI-1206</title>
        <description>Total body clearance after intravenous BI-1206 administration</description>
        <time_frame>Doses 1 and 4 (pre-infusion, end of infusion, +4, +24, +48 and +72 hours)</time_frame>
        <population>Patients who provided serum samples before and after receiving BI-1206 for pharmacokinetic evaluation. One patient was enrolled to Part A, Arm 2 but PK parameters could not be evaluated for this patient, as there were no post-dose samples taken for the patient recruited to this cohort.</population>
        <group_list>
          <group group_id="O1">
            <title>Part A: Arm 1: BI-1206 Single Agent Dose Escalation Phase</title>
            <description>BI-1206 given by IV infusion to all patients once weekly for a period of four weeks, patients will then have a follow-up period of four weeks (8 week period classified as induction therapy).&#xD;
BI-1206 single agent dose escalation phase: BI-1206 single agent dose escalation phase to determine the MTD or MAD and RP2D for evaluation of BI-1206.</description>
          </group>
          <group group_id="O2">
            <title>Part A: Arm 2: Combination of BI-1206 With Rituximab Escalation Phase</title>
            <description>Arm 2, an investigation of combination treatment of BI-1206 with rituximab, involving an initial assessment of the appropriate dose of BI-1206 that can be given in combination with rituximab (combination dose escalation cohorts).&#xD;
Combination of BI-1206 with rituximab escalation phase: An investigation of combination treatment of BI-1206 with rituximab.</description>
          </group>
          <group group_id="O3">
            <title>Part B: Arm1: BI-1206 Single Agent Expansion Phase</title>
            <description>Part B Arm 1, an expansion cohort of up to 25 patients treated with single agent BI-1206 at the RP2D as determined in Part A Arm 1. Expansion to include a minimum of 12 CLL patients and six MCL patients.&#xD;
BI-1206 single agent expansion phase: BI-1206 single agent expansion phase at the RP2D.</description>
          </group>
          <group group_id="O4">
            <title>Part B: Arm 2: Combination of BI-1206 With Rituximab Expansion Phase</title>
            <description>Part B Arm 2, an expansion cohort of up to 25 patients treated with a combination of BI-1206 and rituximab at the RP2D as determined in Part A Arm 2. Expansion to include a minimum of 12 CLL patients and six MCL patients.&#xD;
Combination of BI-1206 with rituximab expansion phase: BI-1206 in combination with rituximab at the RP2D.</description>
          </group>
        </group_list>
        <measure>
          <title>Measurement of PK Parameter Total Body Clearance (CL) for BI-1206</title>
          <description>Total body clearance after intravenous BI-1206 administration</description>
          <population>Patients who provided serum samples before and after receiving BI-1206 for pharmacokinetic evaluation. One patient was enrolled to Part A, Arm 2 but PK parameters could not be evaluated for this patient, as there were no post-dose samples taken for the patient recruited to this cohort.</population>
          <units>mL/h/kg</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="0"/>
                <count group_id="O3" value="0"/>
                <count group_id="O4" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>0.4 - 2 mg BI-1206 (Cohort 1, starting dose and first intra patient escalation dose)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA" lower_limit="NA" upper_limit="NA">CL could not be assessed at these dose levels as insufficient serum concentration values were above the lower limit of detection.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>10 - 50 mg BI-1206 (Cohort 1 intra patient dose escalation)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.34" lower_limit="2.45" upper_limit="10.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>100 mg BI-1206 (Cohort 2) Dose 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.32" lower_limit="1.82" upper_limit="9.63"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>100 mg BI-1206 (Cohort 2) Dose 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.44" lower_limit="6.61" upper_limit="8.64"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Measurement of PK Parameter Volume of Distribution (Vss) for BI-1206</title>
        <description>Volume of distribution after administration of BI-1206</description>
        <time_frame>Doses 1 and 4 (pre-infusion, end of infusion, +4, +24, +48 and +72 hours)</time_frame>
        <population>Patients who provided serum samples before and after receiving BI-1206 for pharmacokinetic evaluation. One patient was enrolled to Part A, Arm 2 but PK parameters could not be evaluated for this patient, as there were no post-dose samples taken for the patient recruited to this cohort.</population>
        <group_list>
          <group group_id="O1">
            <title>Part A: Arm 1: BI-1206 Single Agent Dose Escalation Phase</title>
            <description>BI-1206 given by IV infusion to all patients once weekly for a period of four weeks, patients will then have a follow-up period of four weeks (8 week period classified as induction therapy).&#xD;
BI-1206 single agent dose escalation phase: BI-1206 single agent dose escalation phase to determine the MTD or MAD and RP2D for evaluation of BI-1206.</description>
          </group>
          <group group_id="O2">
            <title>Part A: Arm 2: Combination of BI-1206 With Rituximab Escalation Phase</title>
            <description>Arm 2, an investigation of combination treatment of BI-1206 with rituximab, involving an initial assessment of the appropriate dose of BI-1206 that can be given in combination with rituximab (combination dose escalation cohorts).&#xD;
Combination of BI-1206 with rituximab escalation phase: An investigation of combination treatment of BI-1206 with rituximab.</description>
          </group>
          <group group_id="O3">
            <title>Part B: Arm1: BI-1206 Single Agent Expansion Phase</title>
            <description>Part B Arm 1, an expansion cohort of up to 25 patients treated with single agent BI-1206 at the RP2D as determined in Part A Arm 1. Expansion to include a minimum of 12 CLL patients and six MCL patients.&#xD;
BI-1206 single agent expansion phase: BI-1206 single agent expansion phase at the RP2D.</description>
          </group>
          <group group_id="O4">
            <title>Part B: Arm 2: Combination of BI-1206 With Rituximab Expansion Phase</title>
            <description>Part B Arm 2, an expansion cohort of up to 25 patients treated with a combination of BI-1206 and rituximab at the RP2D as determined in Part A Arm 2. Expansion to include a minimum of 12 CLL patients and six MCL patients.&#xD;
Combination of BI-1206 with rituximab expansion phase: BI-1206 in combination with rituximab at the RP2D.</description>
          </group>
        </group_list>
        <measure>
          <title>Measurement of PK Parameter Volume of Distribution (Vss) for BI-1206</title>
          <description>Volume of distribution after administration of BI-1206</description>
          <population>Patients who provided serum samples before and after receiving BI-1206 for pharmacokinetic evaluation. One patient was enrolled to Part A, Arm 2 but PK parameters could not be evaluated for this patient, as there were no post-dose samples taken for the patient recruited to this cohort.</population>
          <units>mL/kg</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="0"/>
                <count group_id="O3" value="0"/>
                <count group_id="O4" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>0.4 - 2 mg BI-1206 (Cohort 1, starting dose and first intra patient escalation dose)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA" lower_limit="NA" upper_limit="NA">Vss could not be assessed at these dose levels as insufficient serum concentration values were above the lower limit of detection.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>10 - 50 mg BI-1206 (Cohort 1, intra patient dose escalation)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="84.2" lower_limit="60.6" upper_limit="208"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>100 mg BI-1206 (Cohort 2) Dose 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="81.0" lower_limit="50.5" upper_limit="182"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>100 mg BI-1206 (Cohort 2) Dose 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="126" lower_limit="124" upper_limit="143"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Measurement of Anti-drug Antibody (ADA) Response to BI-1206 During the BI-1206 Treatment Period Using ELISA</title>
        <description>Patients with true ADA response</description>
        <time_frame>Pre dose at weeks 1, 5 and 8, maintenance phase and off-study visit.</time_frame>
        <population>Anti-drug antibody response population</population>
        <group_list>
          <group group_id="O1">
            <title>Part A: Arm 1: BI-1206 Single Agent Dose Escalation Phase</title>
            <description>BI-1206 given by IV infusion to all patients once weekly for a period of four weeks, patients will then have a follow-up period of four weeks (8 week period classified as induction therapy).&#xD;
BI-1206 single agent dose escalation phase: BI-1206 single agent dose escalation phase to determine the MTD or MAD and RP2D for evaluation of BI-1206.</description>
          </group>
          <group group_id="O2">
            <title>Part A: Arm 2: Combination of BI-1206 With Rituximab Escalation Phase</title>
            <description>Arm 2, an investigation of combination treatment of BI-1206 with rituximab, involving an initial assessment of the appropriate dose of BI-1206 that can be given in combination with rituximab (combination dose escalation cohorts).&#xD;
Combination of BI-1206 with rituximab escalation phase: An investigation of combination treatment of BI-1206 with rituximab.</description>
          </group>
          <group group_id="O3">
            <title>Part B: Arm1: BI-1206 Single Agent Expansion Phase</title>
            <description>Part B Arm 1, an expansion cohort of up to 25 patients treated with single agent BI-1206 at the RP2D as determined in Part A Arm 1. Expansion to include a minimum of 12 CLL patients and six MCL patients.&#xD;
BI-1206 single agent expansion phase: BI-1206 single agent expansion phase at the RP2D.</description>
          </group>
          <group group_id="O4">
            <title>Part B: Arm 2: Combination of BI-1206 With Rituximab Expansion Phase</title>
            <description>Part B Arm 2, an expansion cohort of up to 25 patients treated with a combination of BI-1206 and rituximab at the RP2D as determined in Part A Arm 2. Expansion to include a minimum of 12 CLL patients and six MCL patients.&#xD;
Combination of BI-1206 with rituximab expansion phase: BI-1206 in combination with rituximab at the RP2D.</description>
          </group>
        </group_list>
        <measure>
          <title>Measurement of Anti-drug Antibody (ADA) Response to BI-1206 During the BI-1206 Treatment Period Using ELISA</title>
          <description>Patients with true ADA response</description>
          <population>Anti-drug antibody response population</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="1"/>
                <count group_id="O3" value="0"/>
                <count group_id="O4" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Measurement of Peripheral Blood B-lymphocyte Depletion During the BI-1206 Treatment Period Using Flow Cytometry.</title>
        <description>Number of patients with B-lymphocyte depletion during BI-1206 treatment period.</description>
        <time_frame>During induction phase (up to 8 weeks).</time_frame>
        <population>B-lymphocyte depletion population</population>
        <group_list>
          <group group_id="O1">
            <title>Part A: Arm 1: BI-1206 Single Agent Dose Escalation Phase</title>
            <description>BI-1206 given by IV infusion to all patients once weekly for a period of four weeks, patients will then have a follow-up period of four weeks (8 week period classified as induction therapy).&#xD;
BI-1206 single agent dose escalation phase: BI-1206 single agent dose escalation phase to determine the MTD or MAD and RP2D for evaluation of BI-1206.</description>
          </group>
          <group group_id="O2">
            <title>Part A: Arm 2: Combination of BI-1206 With Rituximab Escalation Phase</title>
            <description>Arm 2, an investigation of combination treatment of BI-1206 with rituximab, involving an initial assessment of the appropriate dose of BI-1206 that can be given in combination with rituximab (combination dose escalation cohorts).&#xD;
Combination of BI-1206 with rituximab escalation phase: An investigation of combination treatment of BI-1206 with rituximab.</description>
          </group>
          <group group_id="O3">
            <title>Part B: Arm1: BI-1206 Single Agent Expansion Phase</title>
            <description>Part B Arm 1, an expansion cohort of up to 25 patients treated with single agent BI-1206 at the RP2D as determined in Part A Arm 1. Expansion to include a minimum of 12 CLL patients and six MCL patients.&#xD;
BI-1206 single agent expansion phase: BI-1206 single agent expansion phase at the RP2D.</description>
          </group>
          <group group_id="O4">
            <title>Part B: Arm 2: Combination of BI-1206 With Rituximab Expansion Phase</title>
            <description>Part B Arm 2, an expansion cohort of up to 25 patients treated with a combination of BI-1206 and rituximab at the RP2D as determined in Part A Arm 2. Expansion to include a minimum of 12 CLL patients and six MCL patients.&#xD;
Combination of BI-1206 with rituximab expansion phase: BI-1206 in combination with rituximab at the RP2D.</description>
          </group>
        </group_list>
        <measure>
          <title>Measurement of Peripheral Blood B-lymphocyte Depletion During the BI-1206 Treatment Period Using Flow Cytometry.</title>
          <description>Number of patients with B-lymphocyte depletion during BI-1206 treatment period.</description>
          <population>B-lymphocyte depletion population</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="11"/>
                <count group_id="O2" value="0"/>
                <count group_id="O3" value="0"/>
                <count group_id="O4" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Assessment of Best Disease Response According to Criteria for Malignant Lymphoma (Cheson, 2014) Waldenström Macroglobulinaemia Assessment Criteria (Owen 2013, Kimby 2006) or NCI Chronic Lymphocytic Leukaemia (CLL) Criteria (Hallek, 2008).</title>
        <description>To look for signs of anti-tumour activity of BI-1206 alone and in combination in patients with relapsed or refractory B-cell malignancies</description>
        <time_frame>Response evaluated 4 weeks after last dose in induction phase, every 16 weeks during maintenance phase and at off-study.</time_frame>
        <population>Response population</population>
        <group_list>
          <group group_id="O1">
            <title>Part A: Arm 1: BI-1206 Single Agent Dose Escalation Phase</title>
            <description>BI-1206 given by IV infusion to all patients once weekly for a period of four weeks, patients will then have a follow-up period of four weeks (8 week period classified as induction therapy).&#xD;
BI-1206 single agent dose escalation phase: BI-1206 single agent dose escalation phase to determine the MTD or MAD and RP2D for evaluation of BI-1206.</description>
          </group>
          <group group_id="O2">
            <title>Part A: Arm 2: Combination of BI-1206 With Rituximab Escalation Phase</title>
            <description>Arm 2, an investigation of combination treatment of BI-1206 with rituximab, involving an initial assessment of the appropriate dose of BI-1206 that can be given in combination with rituximab (combination dose escalation cohorts).&#xD;
Combination of BI-1206 with rituximab escalation phase: An investigation of combination treatment of BI-1206 with rituximab.</description>
          </group>
          <group group_id="O3">
            <title>Part B: Arm1: BI-1206 Single Agent Expansion Phase</title>
            <description>Part B Arm 1, an expansion cohort of up to 25 patients treated with single agent BI-1206 at the RP2D as determined in Part A Arm 1. Expansion to include a minimum of 12 CLL patients and six MCL patients.&#xD;
BI-1206 single agent expansion phase: BI-1206 single agent expansion phase at the RP2D.</description>
          </group>
          <group group_id="O4">
            <title>Part B: Arm 2: Combination of BI-1206 With Rituximab Expansion Phase</title>
            <description>Part B Arm 2, an expansion cohort of up to 25 patients treated with a combination of BI-1206 and rituximab at the RP2D as determined in Part A Arm 2. Expansion to include a minimum of 12 CLL patients and six MCL patients.&#xD;
Combination of BI-1206 with rituximab expansion phase: BI-1206 in combination with rituximab at the RP2D.</description>
          </group>
        </group_list>
        <measure>
          <title>Assessment of Best Disease Response According to Criteria for Malignant Lymphoma (Cheson, 2014) Waldenström Macroglobulinaemia Assessment Criteria (Owen 2013, Kimby 2006) or NCI Chronic Lymphocytic Leukaemia (CLL) Criteria (Hallek, 2008).</title>
          <description>To look for signs of anti-tumour activity of BI-1206 alone and in combination in patients with relapsed or refractory B-cell malignancies</description>
          <population>Response population</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="13"/>
                <count group_id="O2" value="1"/>
                <count group_id="O3" value="0"/>
                <count group_id="O4" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Stable disease</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Progressive disease</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Not evaluable</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Measure Progression Free Survival at 1 Year After the First BI-1206 Administration on the Study for All Patients</title>
        <description>To measure the time to disease progression and twelve month survival</description>
        <time_frame>From first BI-1206 administration up to 12 months</time_frame>
        <population>Progression free survival population</population>
        <group_list>
          <group group_id="O1">
            <title>Part A: Arm 1: BI-1206 Single Agent Dose Escalation Phase</title>
            <description>BI-1206 given by IV infusion to all patients once weekly for a period of four weeks, patients will then have a follow-up period of four weeks (8 week period classified as induction therapy).&#xD;
BI-1206 single agent dose escalation phase: BI-1206 single agent dose escalation phase to determine the MTD or MAD and RP2D for evaluation of BI-1206.</description>
          </group>
          <group group_id="O2">
            <title>Part A: Arm 2: Combination of BI-1206 With Rituximab Escalation Phase</title>
            <description>Arm 2, an investigation of combination treatment of BI-1206 with rituximab, involving an initial assessment of the appropriate dose of BI-1206 that can be given in combination with rituximab (combination dose escalation cohorts).&#xD;
Combination of BI-1206 with rituximab escalation phase: An investigation of combination treatment of BI-1206 with rituximab.</description>
          </group>
          <group group_id="O3">
            <title>Part B: Arm1: BI-1206 Single Agent Expansion Phase</title>
            <description>Part B Arm 1, an expansion cohort of up to 25 patients treated with single agent BI-1206 at the RP2D as determined in Part A Arm 1. Expansion to include a minimum of 12 CLL patients and six MCL patients.&#xD;
BI-1206 single agent expansion phase: BI-1206 single agent expansion phase at the RP2D.</description>
          </group>
          <group group_id="O4">
            <title>Part B: Arm 2: Combination of BI-1206 With Rituximab Expansion Phase</title>
            <description>Part B Arm 2, an expansion cohort of up to 25 patients treated with a combination of BI-1206 and rituximab at the RP2D as determined in Part A Arm 2. Expansion to include a minimum of 12 CLL patients and six MCL patients.&#xD;
Combination of BI-1206 with rituximab expansion phase: BI-1206 in combination with rituximab at the RP2D.</description>
          </group>
        </group_list>
        <measure>
          <title>Measure Progression Free Survival at 1 Year After the First BI-1206 Administration on the Study for All Patients</title>
          <description>To measure the time to disease progression and twelve month survival</description>
          <population>Progression free survival population</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="13"/>
                <count group_id="O2" value="1"/>
                <count group_id="O3" value="0"/>
                <count group_id="O4" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Progression free &amp; alive</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Progressed, died or unknown</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Measure Overall Survival at 1 Year After the First BI-1206 Administration on the Study for All Patients</title>
        <description>To measure the time to disease progression and twelve month survival</description>
        <time_frame>From first BI-1206 administration up to 12 months. Participants whose last reported status was not death were censored.</time_frame>
        <population>Overall survival population</population>
        <group_list>
          <group group_id="O1">
            <title>Part A: Arm 1: BI-1206 Single Agent Dose Escalation Phase</title>
            <description>BI-1206 given by IV infusion to all patients once weekly for a period of four weeks, patients will then have a follow-up period of four weeks (8 week period classified as induction therapy).&#xD;
BI-1206 single agent dose escalation phase: BI-1206 single agent dose escalation phase to determine the MTD or MAD and RP2D for evaluation of BI-1206.</description>
          </group>
          <group group_id="O2">
            <title>Part A: Arm 2: Combination of BI-1206 With Rituximab Escalation Phase</title>
            <description>Arm 2, an investigation of combination treatment of BI-1206 with rituximab, involving an initial assessment of the appropriate dose of BI-1206 that can be given in combination with rituximab (combination dose escalation cohorts).&#xD;
Combination of BI-1206 with rituximab escalation phase: An investigation of combination treatment of BI-1206 with rituximab.</description>
          </group>
          <group group_id="O3">
            <title>Part B: Arm1: BI-1206 Single Agent Expansion Phase</title>
            <description>Part B Arm 1, an expansion cohort of up to 25 patients treated with single agent BI-1206 at the RP2D as determined in Part A Arm 1. Expansion to include a minimum of 12 CLL patients and six MCL patients.&#xD;
BI-1206 single agent expansion phase: BI-1206 single agent expansion phase at the RP2D.</description>
          </group>
          <group group_id="O4">
            <title>Part B: Arm 2: Combination of BI-1206 With Rituximab Expansion Phase</title>
            <description>Part B Arm 2, an expansion cohort of up to 25 patients treated with a combination of BI-1206 and rituximab at the RP2D as determined in Part A Arm 2. Expansion to include a minimum of 12 CLL patients and six MCL patients.&#xD;
Combination of BI-1206 with rituximab expansion phase: BI-1206 in combination with rituximab at the RP2D.</description>
          </group>
        </group_list>
        <measure>
          <title>Measure Overall Survival at 1 Year After the First BI-1206 Administration on the Study for All Patients</title>
          <description>To measure the time to disease progression and twelve month survival</description>
          <population>Overall survival population</population>
          <units>Days</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="5"/>
                <count group_id="O2" value="0"/>
                <count group_id="O3" value="0"/>
                <count group_id="O4" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="152.2" lower_limit="38" upper_limit="360"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Safety data were collected from the date of written informed consent and continued for 125 days after the final administration of BI 1206 or rituximab</time_frame>
      <desc>Trial terminated before part B opened. No patients in arm B.</desc>
      <group_list>
        <group group_id="E1">
          <title>Part A: Arm 1: BI-1206 Single Agent Dose Escalation Phase</title>
          <description>BI-1206 given by IV infusion to all patients once weekly for a period of four weeks, patients will then have a follow-up period of four weeks (8 week period classified as induction therapy).&#xD;
BI-1206 single agent dose escalation phase: BI-1206 single agent dose escalation phase to determine the MTD or MAD and RP2D for evaluation of BI-1206.</description>
        </group>
        <group group_id="E2">
          <title>Part A: Arm 2: Combination of BI-1206 With Rituximab Escalation Phase</title>
          <description>Arm 2, an investigation of combination treatment of BI-1206 with rituximab, involving an initial assessment of the appropriate dose of BI-1206 that can be given in combination with rituximab (combination dose escalation cohorts).&#xD;
Combination of BI-1206 with rituximab escalation phase: An investigation of combination treatment of BI-1206 with rituximab.</description>
        </group>
        <group group_id="E3">
          <title>Part B: Arm1: BI-1206 Single Agent Expansion Phase</title>
          <description>Part B Arm 1, an expansion cohort of up to 25 patients treated with single agent BI-1206 at the RP2D as determined in Part A Arm 1. Expansion to include a minimum of 12 CLL patients and six MCL patients.&#xD;
BI-1206 single agent expansion phase: BI-1206 single agent expansion phase at the RP2D.</description>
        </group>
        <group group_id="E4">
          <title>Part B: Arm 2: Combination of BI-1206 With Rituximab Expansion Phase</title>
          <description>Part B Arm 2, an expansion cohort of up to 25 patients treated with a combination of BI-1206 and rituximab at the RP2D as determined in Part A Arm 2. Expansion to include a minimum of 12 CLL patients and six MCL patients.&#xD;
Combination of BI-1206 with rituximab expansion phase: BI-1206 in combination with rituximab at the RP2D.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA 23.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="13"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="13"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="0"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title vocab="MedDRA">Atrial fibrillation</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="13"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" subjects_at_risk="0"/>
                <counts group_id="E4" subjects_at_risk="0"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="13"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" subjects_at_risk="0"/>
                <counts group_id="E4" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="13"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" subjects_at_risk="0"/>
                <counts group_id="E4" subjects_at_risk="0"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Non-cardiac chest pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="13"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" subjects_at_risk="0"/>
                <counts group_id="E4" subjects_at_risk="0"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Abdominal abscess</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="13"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" subjects_at_risk="0"/>
                <counts group_id="E4" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>Lower respiratory tract infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="13"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" subjects_at_risk="0"/>
                <counts group_id="E4" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>Metapneumovirus infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="13"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" subjects_at_risk="0"/>
                <counts group_id="E4" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>Neutropenic sepsis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="13"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" subjects_at_risk="0"/>
                <counts group_id="E4" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="13"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" subjects_at_risk="0"/>
                <counts group_id="E4" subjects_at_risk="0"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Infusion related reaction</sub_title>
                <counts group_id="E1" events="11" subjects_affected="5" subjects_at_risk="13"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1"/>
                <counts group_id="E3" subjects_at_risk="0"/>
                <counts group_id="E4" subjects_at_risk="0"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Hyperkalaemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="13"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" subjects_at_risk="0"/>
                <counts group_id="E4" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>Hyperuricaemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="13"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" subjects_at_risk="0"/>
                <counts group_id="E4" subjects_at_risk="0"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="13"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" subjects_at_risk="0"/>
                <counts group_id="E4" subjects_at_risk="0"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Acute kidney injury</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="13"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" subjects_at_risk="0"/>
                <counts group_id="E4" subjects_at_risk="0"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Dyspnoea</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="13"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" subjects_at_risk="0"/>
                <counts group_id="E4" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>Pleural effusion</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="13"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" subjects_at_risk="0"/>
                <counts group_id="E4" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>Respiratory failure</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="13"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" subjects_at_risk="0"/>
                <counts group_id="E4" subjects_at_risk="0"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_vocab>MedDRA 23.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="13" subjects_at_risk="13"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="0"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anaemia</sub_title>
                <counts group_id="E1" events="5" subjects_affected="4" subjects_at_risk="13"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" subjects_at_risk="0"/>
                <counts group_id="E4" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>Thrombocytopenia</sub_title>
                <counts group_id="E1" events="5" subjects_affected="4" subjects_at_risk="13"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" subjects_at_risk="0"/>
                <counts group_id="E4" subjects_at_risk="0"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Tachycardia</sub_title>
                <counts group_id="E1" events="5" subjects_affected="4" subjects_at_risk="13"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1"/>
                <counts group_id="E3" subjects_at_risk="0"/>
                <counts group_id="E4" subjects_at_risk="0"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Blepharitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="13"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" subjects_at_risk="0"/>
                <counts group_id="E4" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>Cataract</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="13"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" subjects_at_risk="0"/>
                <counts group_id="E4" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>Normal tension glaucoma</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="13"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" subjects_at_risk="0"/>
                <counts group_id="E4" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>Periorbital oedema</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="13"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" subjects_at_risk="0"/>
                <counts group_id="E4" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>Vision blurred</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="13"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" subjects_at_risk="0"/>
                <counts group_id="E4" subjects_at_risk="0"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal distension</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="13"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" subjects_at_risk="0"/>
                <counts group_id="E4" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>Abdominal pain upper</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="13"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" subjects_at_risk="0"/>
                <counts group_id="E4" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" events="4" subjects_affected="3" subjects_at_risk="13"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" subjects_at_risk="0"/>
                <counts group_id="E4" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="13"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" subjects_at_risk="0"/>
                <counts group_id="E4" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>Dry mouth</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="13"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" subjects_at_risk="0"/>
                <counts group_id="E4" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>Dyspepsia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="13"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" subjects_at_risk="0"/>
                <counts group_id="E4" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>Flatulence</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="13"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" subjects_at_risk="0"/>
                <counts group_id="E4" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>Lip swelling</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="13"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" subjects_at_risk="0"/>
                <counts group_id="E4" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="6" subjects_affected="5" subjects_at_risk="13"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" subjects_at_risk="0"/>
                <counts group_id="E4" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="13"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" subjects_at_risk="0"/>
                <counts group_id="E4" subjects_at_risk="0"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Chest discomfort</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="13"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" subjects_at_risk="0"/>
                <counts group_id="E4" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>Chills</sub_title>
                <counts group_id="E1" events="7" subjects_affected="6" subjects_at_risk="13"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" subjects_at_risk="0"/>
                <counts group_id="E4" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" events="9" subjects_affected="8" subjects_at_risk="13"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" subjects_at_risk="0"/>
                <counts group_id="E4" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>Feeling cold</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="13"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" subjects_at_risk="0"/>
                <counts group_id="E4" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>Feeling hot</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="13"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" subjects_at_risk="0"/>
                <counts group_id="E4" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>Non-cardiac chest pain</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="13"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" subjects_at_risk="0"/>
                <counts group_id="E4" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>Oedema peripheral</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="13"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" subjects_at_risk="0"/>
                <counts group_id="E4" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>Pain</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="13"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" subjects_at_risk="0"/>
                <counts group_id="E4" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" events="6" subjects_affected="5" subjects_at_risk="13"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" subjects_at_risk="0"/>
                <counts group_id="E4" subjects_at_risk="0"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Folliculitis</sub_title>
                <counts group_id="E1" events="3" subjects_affected="2" subjects_at_risk="13"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" subjects_at_risk="0"/>
                <counts group_id="E4" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>Lower respiratory tract infection</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="13"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" subjects_at_risk="0"/>
                <counts group_id="E4" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>Rhinitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="13"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" subjects_at_risk="0"/>
                <counts group_id="E4" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="13"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" subjects_at_risk="0"/>
                <counts group_id="E4" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="13"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" subjects_at_risk="0"/>
                <counts group_id="E4" subjects_at_risk="0"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Fall</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="13"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" subjects_at_risk="0"/>
                <counts group_id="E4" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>Infusion related reaction</sub_title>
                <counts group_id="E1" events="30" subjects_affected="9" subjects_at_risk="13"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1"/>
                <counts group_id="E3" subjects_at_risk="0"/>
                <counts group_id="E4" subjects_at_risk="0"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Alanine aminotransferase increased</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="13"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1"/>
                <counts group_id="E3" subjects_at_risk="0"/>
                <counts group_id="E4" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>Aspartate aminotransferase increased</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="13"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1"/>
                <counts group_id="E3" subjects_at_risk="0"/>
                <counts group_id="E4" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>Blood creatinine increased</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="13"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" subjects_at_risk="0"/>
                <counts group_id="E4" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>Blood immunoglobulin G decreased</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="13"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" subjects_at_risk="0"/>
                <counts group_id="E4" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>Body temperature increased</sub_title>
                <counts group_id="E1" events="3" subjects_affected="2" subjects_at_risk="13"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" subjects_at_risk="0"/>
                <counts group_id="E4" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>C-reactive protein increased</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="13"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" subjects_at_risk="0"/>
                <counts group_id="E4" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>CD4 lymphocytes decreased</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="13"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" subjects_at_risk="0"/>
                <counts group_id="E4" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>Oxygen saturation decreased</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="13"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" subjects_at_risk="0"/>
                <counts group_id="E4" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>Platelet count decreased</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="13"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1"/>
                <counts group_id="E3" subjects_at_risk="0"/>
                <counts group_id="E4" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>Serum ferritin increased</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="13"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" subjects_at_risk="0"/>
                <counts group_id="E4" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>Weight decreased</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="13"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" subjects_at_risk="0"/>
                <counts group_id="E4" subjects_at_risk="0"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Decreased appetite</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="13"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" subjects_at_risk="0"/>
                <counts group_id="E4" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>Gout</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="13"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" subjects_at_risk="0"/>
                <counts group_id="E4" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>Hyperglycaemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="13"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1"/>
                <counts group_id="E3" subjects_at_risk="0"/>
                <counts group_id="E4" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>Hypomagnesaemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="13"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" subjects_at_risk="0"/>
                <counts group_id="E4" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>Hypophosphataemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="13"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" subjects_at_risk="0"/>
                <counts group_id="E4" subjects_at_risk="0"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="13"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" subjects_at_risk="0"/>
                <counts group_id="E4" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" events="5" subjects_affected="3" subjects_at_risk="13"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" subjects_at_risk="0"/>
                <counts group_id="E4" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>Flank pain</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="13"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" subjects_at_risk="0"/>
                <counts group_id="E4" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>Muscle spasms</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="13"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" subjects_at_risk="0"/>
                <counts group_id="E4" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>Myalgia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="13"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" subjects_at_risk="0"/>
                <counts group_id="E4" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>Neck pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="13"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" subjects_at_risk="0"/>
                <counts group_id="E4" subjects_at_risk="0"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Myelodysplastic syndrome</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="13"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" subjects_at_risk="0"/>
                <counts group_id="E4" subjects_at_risk="0"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="13"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" subjects_at_risk="0"/>
                <counts group_id="E4" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="6" subjects_affected="2" subjects_at_risk="13"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" subjects_at_risk="0"/>
                <counts group_id="E4" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>Lethargy</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="13"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" subjects_at_risk="0"/>
                <counts group_id="E4" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>Paraesthesia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="13"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" subjects_at_risk="0"/>
                <counts group_id="E4" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>Presyncope</sub_title>
                <counts group_id="E1" events="4" subjects_affected="3" subjects_at_risk="13"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" subjects_at_risk="0"/>
                <counts group_id="E4" subjects_at_risk="0"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Anxiety</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="13"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" subjects_at_risk="0"/>
                <counts group_id="E4" subjects_at_risk="0"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="13"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" subjects_at_risk="0"/>
                <counts group_id="E4" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>Dyspnoea</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="13"/>
                <counts group_id="E2" events="2" subjects_affected="1" subjects_at_risk="1"/>
                <counts group_id="E3" subjects_at_risk="0"/>
                <counts group_id="E4" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>Hypoxia</sub_title>
                <counts group_id="E1" events="7" subjects_affected="2" subjects_at_risk="13"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" subjects_at_risk="0"/>
                <counts group_id="E4" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>Oropharyngeal pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="13"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" subjects_at_risk="0"/>
                <counts group_id="E4" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>Wheezing</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="13"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" subjects_at_risk="0"/>
                <counts group_id="E4" subjects_at_risk="0"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Dry skin</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="13"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" subjects_at_risk="0"/>
                <counts group_id="E4" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>Hair texture abnormal</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="13"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" subjects_at_risk="0"/>
                <counts group_id="E4" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>Hyperhidrosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="13"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" subjects_at_risk="0"/>
                <counts group_id="E4" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>Night sweats</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="13"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" subjects_at_risk="0"/>
                <counts group_id="E4" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>Palmar erythema</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="13"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" subjects_at_risk="0"/>
                <counts group_id="E4" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>Pruritus</sub_title>
                <counts group_id="E1" events="8" subjects_affected="2" subjects_at_risk="13"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" subjects_at_risk="0"/>
                <counts group_id="E4" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>Rash maculo-papular</sub_title>
                <counts group_id="E1" events="3" subjects_affected="2" subjects_at_risk="13"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" subjects_at_risk="0"/>
                <counts group_id="E4" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>Urticaria</sub_title>
                <counts group_id="E1" events="25" subjects_affected="8" subjects_at_risk="13"/>
                <counts group_id="E2" events="2" subjects_affected="1" subjects_at_risk="1"/>
                <counts group_id="E3" subjects_at_risk="0"/>
                <counts group_id="E4" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>Palmar-plantar erythrodysaesthesia syndrome</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1"/>
                <counts group_id="E3" subjects_at_risk="0"/>
                <counts group_id="E4" subjects_at_risk="0"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Flushing</sub_title>
                <counts group_id="E1" events="12" subjects_affected="5" subjects_at_risk="13"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" subjects_at_risk="0"/>
                <counts group_id="E4" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>Hot flush</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="13"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" subjects_at_risk="0"/>
                <counts group_id="E4" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" events="8" subjects_affected="4" subjects_at_risk="13"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" subjects_at_risk="0"/>
                <counts group_id="E4" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>Hypotension</sub_title>
                <counts group_id="E1" events="11" subjects_affected="6" subjects_at_risk="13"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1"/>
                <counts group_id="E3" subjects_at_risk="0"/>
                <counts group_id="E4" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>Pallor</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="13"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" subjects_at_risk="0"/>
                <counts group_id="E4" subjects_at_risk="0"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>The trial was terminated early by the Sponsor based on a strategic decision and not a safety related decision. At the time of trial termination, 14 patients had received BI-1206. No patients received rituximab. As a result of the early termination Part B of the trial did not open.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Regulatory Affairs Manager</name_or_title>
      <organization>Cancer Research UK Centre for Drug Development</organization>
      <phone>+44 203 4696878</phone>
      <email>regulatory@cancer.org.uk</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

